Tattooing suspicious axillary lymph nodes in breast cancer patients treated by primary systemic therapy

Conditions

breast cancer C50

de Boniface J, Frisell J, Kühn T, Wiklander-Bråkenhielm I, Dembrower K, Nyman P, Zouzos A, Gerber B, Reimer T, Hartmann S.

2022-04-2218 citations

10.1007/s10549-022-06588-2

Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, Thill M, Rubio IT, Di Micco R, Bonci EA, Niinikoski L, Kontos M, Karadeniz Cakmak G, Hauptmann M, Peintinger F, Pinto D, Matrai Z, Murawa D, Kadayaprath G, Dostalek L, Nina H, Krivorotko P, Classe JM, Schlichting E, Appelgren M, Paluchowski P, Solbach C, Blohmer JU, Kühn T, The Axsana Study Group.

2021-03-29112 citations

10.3390/cancers13071565

Interventions

Group 1: 14G-Core needle biopsy and tattoing (highly purified carbon solution: 0,1-0,5ml Spot) of the largest suspicious axillary under ultrasound guidance and documentation prior primary systemic the

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with primay breast cancer (c/iT1-T4c, uni- or bilateral) diagnosed at the university of Rostock, treated by primary systemic therapy presenting with suspicious axillary lymph nodes (c/i N+) without distant metastases.

Exclusion criteria

Exclusion criteria: - male patients - pregnancy - age < 18 Years - distant metastases - no informed consent

Design outcomes

Primary

Measure	Time frame
detection rate of charcoal tattoed metastatic axillary lymph nodes during surgery after primary systemic therapy in breast cancer patients	—

Secondary

Measure	Time frame
- concordance of SLN and tattooed LN - predictive value of tattoed LN for residual metastatic disease in other axillary lymph nodes - complications caused by tattoing axillary lymph nodes (regarding injection until surgery)	—

Countries

Germany, Sweden

Contacts

Public ContactSteffi Hartmann

Universitätsfrauenklinik

steffi.hartmann@kliniksued-rostock.de0381/44014500

Outcome results

None listed